{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:54:42Z","timestamp":1758815682250},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,10,21]],"date-time":"2014-10-21T00:00:00Z","timestamp":1413849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s00204-014-1385-5","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T04:45:24Z","timestamp":1413953124000},"page":"2233-2242","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies"],"prefix":"10.1007","volume":"88","author":[{"given":"Ellen","family":"Weisberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nonami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,21]]},"reference":[{"key":"1385_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/excr.1999.4732","volume":"254","author":"CL Abram","year":"2000","unstructured":"Abram CL, Courtneidge SA (2000) SRC family tyrosine kinases and growth factor signaling. Exp Cell Res 254:1\u201313","journal-title":"Exp Cell Res"},{"key":"1385_CR2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nchembio760","volume":"2","author":"FJ Adrian","year":"2006","unstructured":"Adrian FJ, Ding Q, Sim T et al (2006) Allosteric inhibitors of BCR-ABL-dependent cell proliferation. Nat Chem Biol 2:95\u2013102","journal-title":"Nat Chem Biol"},{"key":"1385_CR3","doi-asserted-by":"crossref","first-page":"e46674","DOI":"10.1371\/journal.pone.0046674","volume":"7","author":"M Bonifacio","year":"2012","unstructured":"Bonifacio M, Rigo A, Guardalben E, Bergamini C, Cavalieri E, Fato R (2012) \u03b1-Bisabolol is an effective proapoptotic agent against BCR-ABL(+) cells in synergism with imatinib and nilotinib. PLoS One 7:e46674","journal-title":"PLoS One"},{"key":"1385_CR4","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O\u2019Hare T et al (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108:2332\u20132338","journal-title":"Blood"},{"key":"1385_CR5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","volume":"21","author":"C Brendel","year":"2007","unstructured":"Brendel C, Scharenberg C, Dohse M et al (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21:1267\u20131275","journal-title":"Leukemia"},{"key":"1385_CR6","first-page":"M11","volume":"1551","author":"E Buchdunger","year":"2001","unstructured":"Buchdunger E, Matter A, Druker BJ (2001) BCR-ABL inhibition as a modality of CML therapeutics. Biochim Biophys Acta 1551:M11\u2013M18","journal-title":"Biochim Biophys Acta"},{"key":"1385_CR7","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","volume":"102","author":"MR Burgess","year":"2005","unstructured":"Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL (2005) Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 102:3395\u20133400","journal-title":"Proc Natl Acad Sci USA"},{"issue":"31","key":"1385_CR8","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","volume":"102","author":"TA Carter","year":"2005","unstructured":"Carter TA, Wodicka LM, Shah NP et al (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102(31):11011\u201311016","journal-title":"Proc Natl Acad Sci USA"},{"key":"1385_CR9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1479-5876-9-45","volume":"9","author":"E Cavalieri","year":"2011","unstructured":"Cavalieri E, Rigo A, Bonifacio M et al (2011) Pro-apoptotic activity of \u03b1-bisabolol in preclinical models of primary human acute leukemia cells. J Transl Med 9:45","journal-title":"J Transl Med"},{"key":"1385_CR10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1179\/1607845412Y.0000000050","volume":"18","author":"B Chahardouli","year":"2013","unstructured":"Chahardouli B, Zaker F, Mousavi SA et al (2013) Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance. Hematology 18:158\u2013162","journal-title":"Hematology"},{"key":"1385_CR11","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","volume":"19","author":"WW Chan","year":"2011","unstructured":"Chan WW, Wise SC, Kaufman MD et al (2011) Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 19:556\u2013568","journal-title":"Cancer Cell"},{"key":"1385_CR12","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s10637-011-9763-9","volume":"30","author":"JH Cho","year":"2012","unstructured":"Cho JH, Kim KM, Kwon M, Kim JH, Lee J (2012) Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 30:2008\u20132014","journal-title":"Invest New Drugs"},{"key":"1385_CR13","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1021\/jm901808w","volume":"53","author":"HG Choi","year":"2010","unstructured":"Choi HG, Ren P, Adrian F et al (2010) A type-II kinase inhibitor capable of inhibiting the T315I \u201cgatekeeper\u201d mutant of BCR-ABL. J Med Chem 53:5439\u20135448","journal-title":"J Med Chem"},{"key":"1385_CR14","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ et al (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107:4532\u20134539","journal-title":"Blood"},{"key":"1385_CR15","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"J Cortes","year":"2007","unstructured":"Cortes J, Rousselot P, Kim DW et al (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207\u20133213","journal-title":"Blood"},{"key":"1385_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-lbarz J et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1","journal-title":"N Engl J Med"},{"key":"1385_CR17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2141.2011.09016.x","volume":"157","author":"MM Coude","year":"2012","unstructured":"Coude MM, Luycx O, Cariou ME et al (2012) Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation. Br J Haematol 157:407\u2013410","journal-title":"Br J Haematol"},{"key":"1385_CR18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1389557043487321","volume":"4","author":"SW Cowan-Jacob","year":"2004","unstructured":"Cowan-Jacob SW, Guez V, Fendrich G et al (2004) Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 4:285\u2013299","journal-title":"Mini Rev Med Chem"},{"key":"1385_CR19","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1038\/oncsis.2014.3","volume":"3","author":"LJ Crawford","year":"2014","unstructured":"Crawford LJ, Chan ET, Aujay M et al (2014) Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models. Oncogenesis 3:e90","journal-title":"Oncogenesis"},{"key":"1385_CR20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.18388\/abp.2013_2014","volume":"60","author":"K Danisz","year":"2013","unstructured":"Danisz K, Blasiak J (2013) Role of anti-apoptotic pathways activated by BCR\/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors. Acta Biochim Pol 60:503\u2013514","journal-title":"Acta Biochim Pol"},{"key":"1385_CR21","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1021\/jm060727j","volume":"49","author":"J Das","year":"2006","unstructured":"Das J, Chen P, Norris D et al (2006) 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies towards the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib; BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 49:6819\u20136832","journal-title":"J Med Chem"},{"key":"1385_CR22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/CAD.0000000000000093","volume":"25","author":"VA Weger de","year":"2014","unstructured":"de Weger VA, Beijnen JH, Schellens JH (2014) Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel\u2014a review. Anticancer Drugs 25:488\u2013494","journal-title":"Anticancer Drugs"},{"key":"1385_CR23","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343\u20133356","journal-title":"Blood"},{"key":"1385_CR24","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1021\/jm100555f","volume":"53","author":"X Deng","year":"2010","unstructured":"Deng X, Okram B, Ding Q et al (2010) Expanding the diversity of allosteric BCR-ABL inhibitors. J Med Chem 53:6934\u20136946","journal-title":"J Med Chem"},{"key":"1385_CR25","doi-asserted-by":"crossref","first-page":"e83510","DOI":"10.1371\/journal.pone.0083510","volume":"8","author":"J Ding","year":"2013","unstructured":"Ding J, Romani J, Zaborski M et al (2013) Inhibition of PI3K\/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2. PLoS One 8:e83510","journal-title":"PLoS One"},{"key":"1385_CR26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 2:561\u2013566","journal-title":"Nat Med"},{"key":"1385_CR27","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-10-3224","volume":"71","author":"CA Eide","year":"2011","unstructured":"Eide CA, Adrian LT, Tyner JW et al (2011) The ABL switch control inhibitor CDD-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res 71:3189\u20133195","journal-title":"Cancer Res"},{"key":"1385_CR28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/leu.2010.16","volume":"24","author":"JR Engler","year":"2010","unstructured":"Engler JR, Frede A, Saunders VA et al (2010) Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 24:765\u2013770","journal-title":"Leukemia"},{"key":"1385_CR29","doi-asserted-by":"crossref","first-page":"7247","DOI":"10.1021\/jm060897w","volume":"49","author":"D Fancelli","year":"2006","unstructured":"Fancelli D, Moll J, Varasi M et al (2006) 1, 4, 5, 6-Tetrahydropyrrolo[3, 4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 49:7247\u20137251","journal-title":"J Med Chem"},{"key":"1385_CR30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","volume":"123","author":"AK Fielding","year":"2014","unstructured":"Fielding AK, Rowe JM, Buck G et al (2014) UKALLX11\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123:843\u2013850","journal-title":"Blood"},{"key":"1385_CR31","doi-asserted-by":"crossref","unstructured":"Gallipoli P, Cook A, Rhodes S, et al (2014) JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo. Blood 124:1492\u20131501","DOI":"10.1182\/blood-2013-12-545640"},{"key":"1385_CR32","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","volume":"92","author":"C Gambacorti-Passerini","year":"2000","unstructured":"Gambacorti-Passerini C, Barni R, le Coutre P et al (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92:1641\u20131650","journal-title":"J Natl Cancer Inst"},{"key":"1385_CR33","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3892\/or.2014.3070","volume":"31","author":"K Geisler","year":"2014","unstructured":"Geisler K, Reischer A, Kroeger I et al (2014) Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model. Oncol Rep 31:2015\u20132020","journal-title":"Oncol Rep"},{"key":"1385_CR34","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","volume":"109","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Cortes J, Jones D et al (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109:500\u2013502","journal-title":"Blood"},{"key":"1385_CR35","first-page":"375","volume":"63","author":"JM Golas","year":"2003","unstructured":"Golas JM, Arndt K, Etienne C et al (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of SRC and ABL kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63:375\u2013381","journal-title":"Cancer Res"},{"key":"1385_CR36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"1385_CR37","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1073\/pnas.0408283102","volume":"102","author":"K Gumireddy","year":"2005","unstructured":"Gumireddy K, Baker SJ, Cosenza SC et al (2005) A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 102:1992\u20131997","journal-title":"Proc Natl Acad Sci USA"},{"key":"1385_CR38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.2012.063172","volume":"98","author":"R Gurion","year":"2013","unstructured":"Gurion R, Gaffer-Gvili A, Vidal L et al (2013) Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica 98:95\u2013102","journal-title":"Haematologica"},{"key":"1385_CR39","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","volume":"158","author":"C Hegedus","year":"2009","unstructured":"Hegedus C, Ozvegy-Laczka C, Apati A et al (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158:1153\u20131164","journal-title":"Br J Pharmacol"},{"key":"1385_CR40","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190\u20132196","journal-title":"Leukemia"},{"key":"1385_CR41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2002-06-1756","volume":"102","author":"WK Hofmann","year":"2003","unstructured":"Hofmann WK, Komor M, Wassmann B et al (2003) Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102:659\u2013661","journal-title":"Blood"},{"key":"1385_CR42","doi-asserted-by":"crossref","first-page":"e15929","DOI":"10.1371\/journal.pone.0015929","volume":"6","author":"RE Iacob","year":"2011","unstructured":"Iacob RE, Zhang J, Gray NS, Engen JR (2011) Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS One 6:e15929","journal-title":"PLoS One"},{"key":"1385_CR43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12185-012-1005-1","volume":"95","author":"H Itonaga","year":"2012","unstructured":"Itonaga H, Tsushima H, Hata T et al (2012) Successful treatment of a chronic phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon alfa. Int J Hematol 95:209\u2013213","journal-title":"Int J Hematol"},{"key":"1385_CR44","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G et al (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494\u2013500","journal-title":"Blood"},{"key":"1385_CR45","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.2005.01.032","volume":"23","author":"GC Jayson","year":"2005","unstructured":"Jayson GC, Parker GJ, Mullamitha S et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized PEGylated di-Fab, leads to a fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23:973\u2013981","journal-title":"J Clin Oncol"},{"key":"1385_CR46","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542\u20132551","journal-title":"N Engl J Med"},{"key":"1385_CR47","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270","journal-title":"N Engl J Med"},{"key":"1385_CR48","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1111\/j.1582-4934.2010.01218.x","volume":"15","author":"KR Kelly","year":"2011","unstructured":"Kelly KR, Ecsedy J, Medina E et al (2011) The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 15:2057\u20132070","journal-title":"J Cell Mol Med"},{"key":"1385_CR49","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H et al (2005) NS-187, a potent and selective dual BCR-ABL\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106:3948\u20133954","journal-title":"Blood"},{"key":"1385_CR51","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1349-7006.2010.01639.x","volume":"101","author":"M Kodama","year":"2010","unstructured":"Kodama M, Kitadai Y, Sumida T et al (2010) Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor \u03b2 is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci 101:1984\u20131989","journal-title":"Cancer Sci"},{"key":"1385_CR52","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3324\/haematol.2009.016063","volume":"95","author":"M Koldehoff","year":"2010","unstructured":"Koldehoff M, Kordelas L, Beelen DW, Elmaagacli AH (2010) Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. Haematologica 95:388\u2013397","journal-title":"Haematologica"},{"key":"1385_CR53","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1172\/JCI118474","volume":"97","author":"M Kumagai","year":"1996","unstructured":"Kumagai M, Manabe A, Pui CH et al (1996) Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest 97:755\u2013760","journal-title":"J Clin Invest"},{"key":"1385_CR54","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","volume":"95","author":"P Coutre le","year":"2000","unstructured":"le Coutre P, Tassi E, Varella-Garcia M et al (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95:1758\u20131766","journal-title":"Blood"},{"key":"1385_CR55","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","volume":"111","author":"P Coutre le","year":"2008","unstructured":"le Coutre P, Ottmann OG, Giles F et al (2008) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834\u20131839","journal-title":"Blood"},{"key":"1385_CR56","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","volume":"2","author":"Y Liu","year":"2006","unstructured":"Liu Y, Gray NS (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2:358\u2013364","journal-title":"Nat Chem Biol"},{"key":"1385_CR57","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96:1070\u20131079","journal-title":"Blood"},{"key":"1385_CR58","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(02)80599-8","volume":"38","author":"PW Manley","year":"2002","unstructured":"Manley PW, Cowan-Jacob SW, Buchdunger E et al (2002) Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 38:S19\u2013S27","journal-title":"Eur J Cancer"},{"key":"1385_CR59","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1073\/pnas.0511292103","volume":"103","author":"JS Melnick","year":"2006","unstructured":"Melnick JS, Janes J, Kim S et al (2006) An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA 103:3153\u20133158","journal-title":"Proc Natl Acad Sci USA"},{"key":"1385_CR60","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/1471-2407-12-411","volume":"12","author":"AA Mian","year":"2012","unstructured":"Mian AA, Metodieva A, Badura S et al (2012) Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer 12:411","journal-title":"BMC Cancer"},{"key":"1385_CR61","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y et al (2005) Dynamics of chronic myeloid leukaemia. Nature 435:1267\u20131270","journal-title":"Nature"},{"key":"1385_CR62","first-page":"4236","volume":"62","author":"B Nagar","year":"2002","unstructured":"Nagar B, Bornmann WG, Pellicena P et al (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236\u20134243","journal-title":"Cancer Res"},{"key":"1385_CR63","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401\u2013412","journal-title":"Cancer Cell"},{"key":"1385_CR64","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/1078-0432.CCR-05-0622","volume":"11","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP et al (2005) Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src\/Abl inhibitors are compatible with imatinib. Clin Cancer Res 11:6987\u20136993","journal-title":"Clin Cancer Res"},{"key":"1385_CR65","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/cbt.26725","volume":"15","author":"S Okabe","year":"2014","unstructured":"Okabe S, Tauchi T, Tanaka Y et al (2014) Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Cancer Biol Ther 15:207\u2013215","journal-title":"Cancer Biol Ther"},{"key":"1385_CR66","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1593\/neo.131668","volume":"15","author":"M Onoyama","year":"2013","unstructured":"Onoyama M, Kitadai Y, Tanaka Y et al (2013) Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer. Neoplasia 15:1391\u20131399","journal-title":"Neoplasia"},{"key":"1385_CR67","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cytogfr.2004.03.002","volume":"15","author":"A Ostman","year":"2004","unstructured":"Ostman A (2004) PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15:275\u2013286","journal-title":"Cytokine Growth Factor Rev"},{"key":"1385_CR68","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/CAD.0b013e328352cc50","volume":"23","author":"MA Pantaleo","year":"2012","unstructured":"Pantaleo MA, Nannini M, Saponara M et al (2012) Impressive long-term stabilization by nilotinib in two pretreated patients with KIT\/PDGFRA wild-type metastatic gastrointestinal stromal tumors. Anticancer Drugs 23:567\u2013572","journal-title":"Anticancer Drugs"},{"key":"1385_CR69","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/leu.2011.76","volume":"25","author":"R Parameswaran","year":"2011","unstructured":"Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N (2011) Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 25:1314\u20131323","journal-title":"Leukemia"},{"key":"1385_CR70","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"M Puttini","year":"2006","unstructured":"Puttini M, Coluccia AM, Boschelli F (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib resistant BCR-ABL+ neoplastic cells. Cancer Res 66:11314\u201311322","journal-title":"Cancer Res"},{"key":"1385_CR71","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00280-009-1158-7","volume":"66","author":"A Radujkovic","year":"2010","unstructured":"Radujkovic A, Fruehauf S, Zeller WJ, Ho AD, Topaly J (2010) Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells. Cancer Chemother Pharmacol 66:255\u2013264","journal-title":"Cancer Chemother Pharmacol"},{"key":"1385_CR72","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","volume":"109","author":"A Ray","year":"2007","unstructured":"Ray A, Cowan-Jacob SW, Manley PW et al (2007) Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109:5011\u20135015","journal-title":"Blood"},{"key":"1385_CR73","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/08977199209046408","volume":"7","author":"W Risau","year":"1992","unstructured":"Risau W, Drexler H, Mironov V et al (1992) Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7:261\u2013266","journal-title":"Growth Factors"},{"key":"1385_CR74","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","volume":"100","author":"C Roche-Lestienne","year":"2002","unstructured":"Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N et al (2002) Several types of mutations of the ABL gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100:1014\u20131018","journal-title":"Blood"},{"key":"1385_CR75","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I Roeder","year":"2006","unstructured":"Roeder I, Horn M, Glauche I et al (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 12:1181\u20131184","journal-title":"Nat Med"},{"key":"1385_CR76","doi-asserted-by":"crossref","first-page":"10700","DOI":"10.1073\/pnas.162140299","volume":"99","author":"S Rourmiantsev","year":"2002","unstructured":"Rourmiantsev S, Shah NP, Gorre ME et al (2002) Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the ABL kinase domain P-loop. Proc Natl Acad Sci USA 99:10700\u201310705","journal-title":"Proc Natl Acad Sci USA"},{"key":"1385_CR77","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S et al (2010) ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259","journal-title":"N Engl J Med"},{"key":"1385_CR78","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289:1938\u20131942","journal-title":"Science"},{"key":"1385_CR80","doi-asserted-by":"crossref","unstructured":"Schneider M, Korzeniewski N, Merkle K, et al (2014) The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal- Implications for targeted therapies. Urol Oncol. doi: 10.1016\/j.urolonc.2014.06.001","DOI":"10.1016\/j.urolonc.2014.06.001"},{"key":"1385_CR81","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117\u2013125","journal-title":"Cancer Cell"},{"key":"1385_CR82","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399\u2013401","journal-title":"Science"},{"key":"1385_CR83","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah NP, Skaggs BJ, Branford S et al (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117:2562\u20132569","journal-title":"J Clin Invest"},{"key":"1385_CR84","doi-asserted-by":"crossref","first-page":"e7520","DOI":"10.1371\/journal.pone.0007520","volume":"4","author":"T Shen","year":"2009","unstructured":"Shen T, Kuang YH, Ashby CR et al (2009) Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One 4:e7520","journal-title":"PLoS One"},{"key":"1385_CR85","doi-asserted-by":"crossref","first-page":"E4437","DOI":"10.1073\/pnas.1314712110","volume":"110","author":"L Skora","year":"2013","unstructured":"Skora L, Mestan J, Fabbro D, Jahnke W, Grzesiek S (2013) NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proc Natl Acad Sci USA 110:E4437\u2013E4445","journal-title":"Proc Natl Acad Sci USA"},{"key":"1385_CR86","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"S Soverini","year":"2005","unstructured":"Soverini S, Martinelli G, Rosti G et al (2005) ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 23:4100\u20134109","journal-title":"J Clin Oncol"},{"key":"1385_CR87","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Eng J Med 354:2531\u20132541","journal-title":"N Eng J Med"},{"key":"1385_CR88","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1038\/onc.2011.3","volume":"30","author":"T Tauchi","year":"2011","unstructured":"Tauchi T, Okabe S, Ashihara E, Kimura S, Maekawa T, Ohyashiki K (2011) Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen. Oncogene 30:2789\u20132797","journal-title":"Oncogene"},{"key":"1385_CR89","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2009.04.002","volume":"78","author":"AK Tiwari","year":"2009","unstructured":"Tiwari AK, Sodani K, Wang SR et al (2009) Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1\/Pgp and ABCG2\/BCRP\/MXR transporters. Biochem Pharmacol 78:153\u2013161","journal-title":"Biochem Pharmacol"},{"key":"1385_CR90","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CY et al (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790\u20135797","journal-title":"Cancer Res"},{"key":"1385_CR91","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292","journal-title":"Blood"},{"key":"1385_CR92","doi-asserted-by":"crossref","first-page":"e37735","DOI":"10.1371\/journal.pone.0037735","volume":"7","author":"VH Villar","year":"2012","unstructured":"Villar VH, Vogler O, Martinez-Serra J et al (2012) Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft-tissue sarcomas. PLoS One 7:e37735","journal-title":"PLoS One"},{"key":"1385_CR93","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","volume":"359","author":"N Bubnoff Von","year":"2002","unstructured":"Von Bubnoff N, Schneller F, Peschel C, Duyster J (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359:487\u2013491","journal-title":"Lancet"},{"key":"1385_CR94","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","volume":"108","author":"N Bubnoff Von","year":"2006","unstructured":"Von Bubnoff N, Manley PW, Mestan J et al (2006) BCR-ABL resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108:1328\u20131333","journal-title":"Blood"},{"key":"1385_CR95","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/dmd.113.053793","volume":"42","author":"Y Wang","year":"2014","unstructured":"Wang Y, Wang M, Qi H et al (2014) Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug\u2013drug interaction potentials. Drug Metab Dispos 42:782\u2013795","journal-title":"Drug Metab Dispos"},{"key":"1385_CR96","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","volume":"95","author":"E Weisberg","year":"2000","unstructured":"Weisberg E, Griffin JD (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines. Blood 95:3498\u20133505","journal-title":"Blood"},{"key":"1385_CR97","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 7:129\u2013141","journal-title":"Cancer Cell"},{"key":"1385_CR98","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2006-06-026377","volume":"109","author":"E Weisberg","year":"2007","unstructured":"Weisberg E, Catley L, Wright RD et al (2007) Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 109:2112\u20132120","journal-title":"Blood"},{"key":"1385_CR99","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1182\/blood-2007-09-114454","volume":"111","author":"E Weisberg","year":"2008","unstructured":"Weisberg E, Banerji L, Wright RD et al (2008a) Potentiation of antileukemic therapies by the dual PI3K\/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood 111:3723\u20133734","journal-title":"Blood"},{"key":"1385_CR100","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/1535-7163.MCT-07-2331","volume":"7","author":"E Weisberg","year":"2008","unstructured":"Weisberg E, Wright RD, McMillin DW et al (2008b) Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 7:1121\u20131129","journal-title":"Mol Cancer Ther"},{"key":"1385_CR101","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood-2009-11-251751","volume":"115","author":"E Weisberg","year":"2010","unstructured":"Weisberg E, Choi HG, Ray A et al (2010) Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood 115:4206\u20134216","journal-title":"Blood"},{"key":"1385_CR102","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.360","volume":"26","author":"E Weisberg","year":"2012","unstructured":"Weisberg E, Azab AK, Manley PW et al (2012) Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 26:985\u2013990","journal-title":"Leukemia"},{"key":"1385_CR103","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL, Saunders VA, Dang P et al (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697\u2013704","journal-title":"Blood"},{"key":"1385_CR104","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1038\/sj.onc.1205653","volume":"21","author":"M Wilda","year":"2002","unstructured":"Wilda M, Fuchs U, Wossmann W, Borkhardt A (2002) Killing of leukemic cells with a BCR\/ABL fusion gene by RNA interference (RNAi). Oncogene 21:5716\u20135724","journal-title":"Oncogene"},{"key":"1385_CR105","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/blood-2002-12-3899","volume":"102","author":"L Wohlbold","year":"2003","unstructured":"Wohlbold L, van der Kuip H, Miething C et al (2003) Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 102:2236\u20132239","journal-title":"Blood"},{"key":"1385_CR106","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","volume":"100","author":"J Wu","year":"2008","unstructured":"Wu J, Meng F, Kong LY et al (2008) Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 100:926\u2013939","journal-title":"J Natl Cancer Inst"},{"key":"1385_CR107","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/1535370213492689","volume":"238","author":"Y Xia","year":"2013","unstructured":"Xia Y, Fang H, Zhang J, Du Y (2013) Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide. Exp Biol Med (Maywood) 238:932\u2013942","journal-title":"Exp Biol Med (Maywood)"},{"key":"1385_CR108","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.leukres.2011.12.018","volume":"36","author":"H Xing","year":"2012","unstructured":"Xing H, Yang X, Liu T, Lin J, Chen X, Gong Y (2012) The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line. Leuk Res 36:509\u2013513","journal-title":"Leuk Res"},{"key":"1385_CR109","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","volume":"463","author":"J Zhang","year":"2010","unstructured":"Zhang J, Adrian FJ, Jahnke W et al (2010) Targeting BCR-ABL by combining allosteric with ATP-binding site inhibitors. Nature 463:501\u2013506","journal-title":"Nature"},{"key":"1385_CR110","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000333107","volume":"127","author":"GR Zhu","year":"2012","unstructured":"Zhu GR, Ji O, Ji JM et al (2012) Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML. Acta Haematol 127:152\u2013155","journal-title":"Acta Haematol"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-014-1385-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00204-014-1385-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-014-1385-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T01:39:31Z","timestamp":1598405971000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00204-014-1385-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,21]]},"references-count":108,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1385"],"URL":"https:\/\/doi.org\/10.1007\/s00204-014-1385-5","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,21]]}}}